Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance
Oral cancer pain remains a significant public health concern. Despite the development of improved treatments, pain continues to be a debilitating clinical feature of the disease, leading to reduced oral mobility and diminished quality of life. Opioids are the gold standard treatment for moderate-to-...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/11/1558 |
| _version_ | 1827639047404650496 |
|---|---|
| author | Maria Daniela Santi Morgan Zhang Naijiang Liu Chi T. Viet Tongxin Xie Dane D. Jensen Moran Amit Huilin Pan Yi Ye |
| author_facet | Maria Daniela Santi Morgan Zhang Naijiang Liu Chi T. Viet Tongxin Xie Dane D. Jensen Moran Amit Huilin Pan Yi Ye |
| author_sort | Maria Daniela Santi |
| collection | DOAJ |
| description | Oral cancer pain remains a significant public health concern. Despite the development of improved treatments, pain continues to be a debilitating clinical feature of the disease, leading to reduced oral mobility and diminished quality of life. Opioids are the gold standard treatment for moderate-to-severe oral cancer pain; however, chronic opioid administration leads to hyperalgesia, tolerance, and dependence. The aim of this review is to present accumulating evidence that epidermal growth factor receptor (EGFR) signaling, often dysregulated in cancer, is also an emerging signaling pathway critically involved in pain and opioid tolerance. We presented preclinical and clinical data to demonstrate how repurposing EGFR inhibitors typically used for cancer treatment could be an effective pharmacological strategy to treat oral cancer pain and to prevent or delay the development of opioid tolerance. We also propose that EGFR interaction with the µ-opioid receptor and glutamate N-methyl-D-aspartate receptor could be two novel downstream mechanisms contributing to pain and morphine tolerance. Most data presented here support that repurposing EGFR inhibitors as non-opioid analgesics in oral cancer pain is promising and warrants further research. |
| first_indexed | 2024-03-09T16:32:14Z |
| format | Article |
| id | doaj.art-514503f972d04e0aa73dfa3114d341f9 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T16:32:14Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-514503f972d04e0aa73dfa3114d341f92023-11-24T15:00:14ZengMDPI AGPharmaceuticals1424-82472023-11-011611155810.3390/ph16111558Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid ToleranceMaria Daniela Santi0Morgan Zhang1Naijiang Liu2Chi T. Viet3Tongxin Xie4Dane D. Jensen5Moran Amit6Huilin Pan7Yi Ye8Translational Research Center, College of Dentistry, New York University, New York, NY 10010, USATranslational Research Center, College of Dentistry, New York University, New York, NY 10010, USATranslational Research Center, College of Dentistry, New York University, New York, NY 10010, USADepartment of Oral and Maxillofacial Surgery, School of Dentistry, Loma Linda University, Loma Linda, CA 92350, USADepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USATranslational Research Center, College of Dentistry, New York University, New York, NY 10010, USADepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USACenter for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USATranslational Research Center, College of Dentistry, New York University, New York, NY 10010, USAOral cancer pain remains a significant public health concern. Despite the development of improved treatments, pain continues to be a debilitating clinical feature of the disease, leading to reduced oral mobility and diminished quality of life. Opioids are the gold standard treatment for moderate-to-severe oral cancer pain; however, chronic opioid administration leads to hyperalgesia, tolerance, and dependence. The aim of this review is to present accumulating evidence that epidermal growth factor receptor (EGFR) signaling, often dysregulated in cancer, is also an emerging signaling pathway critically involved in pain and opioid tolerance. We presented preclinical and clinical data to demonstrate how repurposing EGFR inhibitors typically used for cancer treatment could be an effective pharmacological strategy to treat oral cancer pain and to prevent or delay the development of opioid tolerance. We also propose that EGFR interaction with the µ-opioid receptor and glutamate N-methyl-D-aspartate receptor could be two novel downstream mechanisms contributing to pain and morphine tolerance. Most data presented here support that repurposing EGFR inhibitors as non-opioid analgesics in oral cancer pain is promising and warrants further research.https://www.mdpi.com/1424-8247/16/11/1558oral cancer painEGFRmorphine toleranceµ-opioid receptorNMDA receptor |
| spellingShingle | Maria Daniela Santi Morgan Zhang Naijiang Liu Chi T. Viet Tongxin Xie Dane D. Jensen Moran Amit Huilin Pan Yi Ye Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance Pharmaceuticals oral cancer pain EGFR morphine tolerance µ-opioid receptor NMDA receptor |
| title | Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance |
| title_full | Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance |
| title_fullStr | Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance |
| title_full_unstemmed | Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance |
| title_short | Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance |
| title_sort | repurposing egfr inhibitors for oral cancer pain and opioid tolerance |
| topic | oral cancer pain EGFR morphine tolerance µ-opioid receptor NMDA receptor |
| url | https://www.mdpi.com/1424-8247/16/11/1558 |
| work_keys_str_mv | AT mariadanielasanti repurposingegfrinhibitorsfororalcancerpainandopioidtolerance AT morganzhang repurposingegfrinhibitorsfororalcancerpainandopioidtolerance AT naijiangliu repurposingegfrinhibitorsfororalcancerpainandopioidtolerance AT chitviet repurposingegfrinhibitorsfororalcancerpainandopioidtolerance AT tongxinxie repurposingegfrinhibitorsfororalcancerpainandopioidtolerance AT danedjensen repurposingegfrinhibitorsfororalcancerpainandopioidtolerance AT moranamit repurposingegfrinhibitorsfororalcancerpainandopioidtolerance AT huilinpan repurposingegfrinhibitorsfororalcancerpainandopioidtolerance AT yiye repurposingegfrinhibitorsfororalcancerpainandopioidtolerance |